Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. | Despite ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

Recent lawsuits from nonprofits, state attorneys general, unions and local governments say the reorganizations and reductions ...

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...

Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labelled ...

Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage ...

In this Fierce Biotech discussion, Chris Hayden speaks with Arnon Chait, PhD, co-founder and CEO of Cleveland Diagnostics, ...

| Tech transfer is conceptually a straightforward process, but it is fraught with minutiae and unknowns that can introduce ...

We hoped industry layoffs would relent in 2024. That's not what happened. Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So, here we are ...